Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:58:34.116Z.
Calculation as of: 2026-10-06T19:58:34.116Z.
Quote observation: 2026-10-06T19:55:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Prelude Therapeutics Incorporated
Market Cap
$215.58M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$217.50M
EV/EBITDA Ratio
N/A
TTM Avg
1.40x
3Y Avg
1.40x
5Y Avg
1.40x
Market Cap
$212.65M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.25M
EV/EBITDA Ratio
14.17x
TTM Avg
22.76x
3Y Avg
55.61x
5Y Avg
55.61x
Market Cap
$211.53M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.68M
EV/EBITDA Ratio
N/A
TTM Avg
14.91x
3Y Avg
15.90x
5Y Avg
15.90x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $215.58M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $217.50M | N/A | 1.40x | 1.40x | 1.40x |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.94M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $212.65M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 14.17x | 22.76x | 55.61x | 55.61x |
| Sionna Therapeutics, Inc. (SION)vs › | $211.53M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A | 6.24x | 9.83x | 9.83x |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.68M | N/A | 14.91x | 15.90x | 15.90x |
| Pro-Dex, Inc. (PDEX)vs › | $208.44M | 15.18x | 13.21x | 12.70x | 13.38x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
